We're #hiring a new Director, IT in Malvern, Pennsylvania. Apply today or share this post with your network.
概要
Fujirebio is a global leader in the field of high-quality in vitro diagnostics (IVD). We are an R&D-driven company constantly developing new technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams located in Japan, Asia, Europe and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials in order to supply, develop or manufacture diagnostic solutions on a wide variety of platforms. Through this business model, we ensure that the potentially life-changing diagnostic markers meet the largest global need in the shortest possible time. Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions. Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network. Fujirebio is today a consolidated subsidiary of H.U. Group Holdings, Inc. (listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1,200 people in Asia, Europe and America.
- ウェブサイト
-
http://www.fujirebio.com
Fujirebioの外部リンク
- 業種
- バイオテクノロジー研究
- 会社規模
- 社員 1,001 - 5,000名
- 本社
- Minato-ku, Tokyo
- 種類
- 上場企業
- 創立
- 1950
- 専門分野
- IVD、in vitro diagnostics、immunoassays、molecular diagnostics、multiparameter testing、strip-based diagnostics、infectious diseases、tumour markers、genetic testing、thyroid、fertility、tissue typing、neurodegeneration、bone testing、alzheimer's disease、virology、line immunoassays、CDMO、OEM、parkinson's disease、multiple sclerosis、HPV、DNA methylation、molecular biology
場所
Fujirebioの社員
アップデート
-
Join us for the first edition of our new webinar series: Neuro Biomarker TALKS! Discover how leading researchers are unlocking the biology of dementia with Lewy bodies. 🧠 Save your spot for this insightful session on November 19th, 2025. Register now via: https://lnkd.in/eX9R_VbY
-
We're #hiring a new Warehouse supervisor in Ghent, Flemish Region. Apply today or share this post with your network.
-
Fujirebioさんが再投稿しました
Today, we are highlighting two of our 2025 Top Innovations winners from the Healthcare and Lab Research Tools categories! 🏆 The Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio Test from Fujirebio offers a blood-based method to detect Alzheimer’s disease biomarkers. Learn how it enables earlier diagnosis: https://lnkd.in/gykwc5in The Well-Watcher from Labrat d'Or is a pipette tracking device that helps scientists keep tabs on where in their 96-well plate they’ve pipetted. Learn how it provides confidence and prevents errors: https://lnkd.in/gwCcE7Ke Stay tuned as we continue to highlight this year's winners!
-
-
We're #hiring a new Controller in Ghent, Flemish Region. Apply today or share this post with your network.
-
We're #hiring a new Warehouse supervisor in Ghent, Flemish Region. Apply today or share this post with your network.
-
🧠 How do YOU confirm the presence of amyloid in Alzheimer’s diagnosis? The American Medical Journal, with support from Novo Nordisk, just launched a powerful interactive infographic that explores the evolving diagnostic landscape—from clinical symptoms to blood-based biomarkers like pTau 217 and β-Amyloid 1-42. At Fujirebio, we’re proud to support initiatives that advance early detection and empower clinicians with tools that improve patient outcomes. 📊 Dive into the infographic to see how diagnostic pathways are shifting—and why it matters. 🔗https://lnkd.in/ehntaCJf #alzheimersawareness #neurodiagnostics #biomarkers #earlydiagnosis #fujirebio #novonordisk #ptau217 #amyloidtesting
-
-
📢 We’re thrilled to announce that Fujirebio has been named a winner in The Scientist’s 2025 Top Innovations contest! Our Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio Test was recognized in the Healthcare and Diagnostics category for its transformative impact on Alzheimer’s disease (AD) diagnostics. As the first FDA-cleared blood-based biomarker of its kind, it offers a minimally invasive, cost-effective alternative to PET scans and CSF testing—offering timely insights to support informed decision-making for clinicians and their patients. This honor celebrates our team’s commitment to advancing diagnostic science and improving lives through innovation. Thank you to The Scientist for this recognition! Learn more about the award honor: https://lnkd.in/eb9-tkYw #topinnovations #alzheimers #diagnostics #fujirebio #innovation #healthcare #alzheimersawareness
-
-
Fujirebioさんが再投稿しました
💜 Today is World Alzheimer’s Day: a day to stand with everyone affected by Alzheimer’s disease, patients and their loved ones alike. Alzheimer’s is a complex disease with many pathological processes. At ADx, we contribute by advancing novel fluid biomarkers as early and reliably as possible through ADxPLORER, so they can prove their value and potentially grow into full RUO or IVD kits. As part of Fujirebio’s NExT Funnel, we help accelerate the path from discovery to clinical implementation. Supporting progress and hope in the fight against Alzheimer’s. 🌍 #WorldAlzheimersDay #FluidBiomarkers #ADxPLORER #NExT
-
On 🧠 World Alzheimer’s Day, we honor the millions of individuals and families affected by Alzheimer’s disease (AD). At Fujirebio we reaffirm our commitment to advancing early, accessible, and reliable in vitro diagnostics. ❤️ 🧪 For over three decades, we have been at the forefront of AD diagnostics, pioneering breakthrough solutions that have transformed our understanding of the disease and the way AD is being diagnosed. The year 2025 marks a historic milestone: 🩸 The Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio Test became the first FDA-cleared blood-based test to aid in identifying amyloid pathology associated with AD in the United States. Today, in an age where early diagnosis and personalized treatment are becoming increasingly crucial, we are proud to stand as the trusted expert partner in neurological disease testing. We continue advancing the NExT generation of biomarkers, including NPTX2, sTREM2, GFAP, and more. More information here 👉 https://lnkd.in/e7BtcJWz #worldalzheimersday #alzheimersawareness #fujirebio #neurodiagnostics #biomarkers #fdacleared #lumipulse #ptau217 #betaamyloid #bloodtest #neurodegeneration